Agilis Biotherapeutics
Welcome to Agilis - Agilis Website
About Agilis Biotherapeutics
Agilis Biotherapeutics, founded in 2013, operated as a biotechnology firm concentrated on developing DNA-based therapeutics for rare, life-threatening genetic diseases affecting the central nervous system (CNS). The company's core strategy involved creating treatments to rectify underlying genetic defects by introducing a corrected gene copy to targeted cells. This approach aimed to provide lasting efficacy for patients with debilitating and often fatal conditions that had few or no treatment options.
The company's business model was centered on the research and development of a pipeline of gene therapies, with the ultimate goal of commercialization and providing these treatments to patients globally. Agilis focused on rare monogenic diseases, which are caused by the malfunction of a single gene. Its primary clients were patients suffering from these specific rare CNS disorders. The company's lead candidate, GT-AADC, was developed for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency, a severe CNS disorder caused by mutations in the DDC gene that leads to a lack of motor control. Clinical studies of GT-AADC showed that a single treatment resulted in significant and durable gains in motor and cognitive functions over several years. The pipeline also included preclinical programs for Friedreich's ataxia (GT-FA) and Angelman syndrome (GT-AS).
A key figure in the company's later stage was Dr. Mark Pykett, who served as President and CEO. In July 2018, PTC Therapeutics announced its agreement to acquire Agilis Biotherapeutics, a deal that was finalized in August 2018. The acquisition was valued at approximately $200 million upfront, comprising $50 million in cash and $150 million in PTC stock, with potential future payments tied to developmental, regulatory, and commercial milestones. The strategic acquisition allowed PTC Therapeutics to absorb Agilis's specialized gene therapy platform, its experienced team, and its pipeline, significantly enhancing PTC's capabilities in treating rare diseases.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jul 2018 | $200M | $200M | PTC Therapeutics | — |
| EARLY VCEquity / VC | Feb 2017 | $13M | $51M | Sands Capital Management | — |
Growth signals
Latest recorded traffic for Agilis Biotherapeutics is 100 monthly website visits, down 33.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Elita GeneticsStem cell banking for pets, offering regenerative treatments to enhance health and reduce future medical costs |
Melbourne, Australia | Operational | 12 | $712K | $2.8M |
Victory GenomicsEquine whole genome sequencing for performance and health |
Guilford, United States | Operational | |||
qGenomicsA biotech company, operating in the diagnostic market and based in Barcelona |
Barcelona, Spain | Acquired | |||
QSAM BiosciencesTreating cancer in children and adults with targeted radiotherapeutics |
Austin, United States | Acquired | |||
Biome DiagnosticsMicrobiome-based diagnostics for precision oncology and healthcare |
Vienna, Austria | Operational | |||
evidnetProvides evidence-based medicine to patients |
Seoul, South Korea | Operational | |||
SeriTechInnovative Health and Skin Care |
Barcelona, Spain | Operational | |||
Mimosa TherapeuticsOffering research-grade natural psilocybin and drug potency test kits |
United States | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Agilis Biotherapeutics in the New York City ecosystem
The Agilis Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Sands Capital Management
Other known investors1 additional known investor
PTC Therapeutics
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Agilis Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Agilis Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







